GlassScriptPhysician profile
Michael James Roche
NPI 1568415313
$3,459.62
in general payments reported to CMS, 2019-2025
22 companies · $709 in 2025
The $709 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $341 · 2023: $1,665 · 2024: $378 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Travel and Lodging: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.56 |
| Travel and Lodging | $778.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,549.18 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Collegium Pharmaceutical, INC. | $627.44 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.93 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $164.39 | 2021-2025 | Levorphanol Tartrate |
| Abbott Laboratories | $159.99 | 2023-2024 | Eterna, Proclaim |
| Vertex Pharmaceuticals Incorporated | $133.75 | 2024-2025 | |
| Saluda Medical Americas, INC. | $109.66 | 2025 | Evoke |
| Averitas Pharma INC. | $65.96 | 2024 | Qutenza |
| Nevro Corp. | $57.74 | 2023-2024 | Senza |
| Spr Therapeutics, INC | $55.73 | 2025 | Sprint Pns System |
| Pfizer INC. | $37.45 | 2021 | |
| Boston Scientific Corporation | $33.93 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $33.16 | 2021 | |
| Biodelivery Sciences International, INC. | $27.04 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.19 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $24.01 | 2024 | |
| Valinor Pharma, LLC | $23.75 | 2025 | Movantik |
| Scilex Pharmaceuticals INC. | $23.25 | 2022 | |
| Vertos Medical, INC. | $20.78 | 2022 | |
| Uswm, LLC | $18.95 | 2021 | |
| Forte Bio-Pharma LLC | $18.05 | 2021 | |
| Redhill Biopharma INC. | $17.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.